United States: Federal Jury Acquits Former Warner Chilcott President

On June 17, 2016, a federal jury in the District of Massachusetts acquitted Carl Reichel, the former president of specialty pharmaceutical manufacturer Warner Chilcott, on a single count of conspiracy to violate the federal Anti-Kickback Statute. Reichel was accused of having orchestrated a company-wide scheme to bribe doctors and medical office staff with lavish meals and speaker fees in exchange for writing more prescriptions of the company's osteoporosis and contraceptive drugs. Reichel was indicted just weeks after the Department of Justice announced, through the "Yates Memo," its initiative to pursue charges against individual defendants more aggressively in connection with corporate misconduct.

Reichel's acquittal, following a three-week trial featuring numerous cooperating and immunized witnesses, can be seen as an example of the obstacles faced by the government in proving allegations that high-ranking corporate officials directed misconduct that took place primarily at lower levels of the company.

A. Warner Chilcott's Plea Agreement

Reichel's acquittal follows the company's October 2015 guilty plea in which it admitted to crimes in connection with sales force misconduct. This included a plea to allegations that the company paid kickbacks, in the form of lavish dinners, speaker fees, and other remuneration, as part of Medical Education or "Med Ed" programs that frequently contained little or no clinical content.

In particular, the company admitted that it provided the sales force with virtually-unlimited expense accounts for programs that the government claimed were largely social events. Additionally, sales representatives selected high-prescribing doctors as speakers at these events, but the speakers generally did not engage in an in-depth clinical discussion about the product, or sometimes even attend the events at all. According to the company's guilty plea, sales representatives were instructed to tell doctors that if they wanted to continue receiving speaker fees, they needed to maintain "clinical experience" with Warner Chilcott products. According to the government, "clinical experience" was a code word for prescribing a higher volume of product. In addition, the government alleged that the company imposed a market share requirement for speakers, requiring these speakers to prescribe a certain percentage of the Company's osteoporosis drug Atelvia.

In its October 2015 plea, the company also pleaded guilty to a federal Health Care Fraud offense in connection with an alleged scheme to manipulate prior authorizations to induce insurance companies to pay for prescriptions. Specifically, the government alleged that sales representatives were instructed to coach doctors and staff, providing "canned" justification language for prior authorization forms that would result in a successful prescription, without regard to whether the justification was true for a particular patient. Additionally, sales representatives were instructed to take the staff responsible for submitting prior authorizations out to lavish dinners or lunches in order to convince the staff to submit the forms. Finally, the company admitted that in many instances, sales representatives around the country actually filled out the prior authorization forms themselves, often providing the "canned" language, and in the process viewing patient information in violation of the Health Insurance Portability and Accountability Act ("HIPAA").1

B. Prosecution of Other Individuals

In addition to Reichel, the government pursued several other individuals in connection with the Warner Chilcott investigation. Three former district managers were indicted and pleaded guilty to conspiracy to commit healthcare fraud and to HIPAA violations (in connection with the alleged prior authorization misconduct).Two of these district managers testified as government witnesses during the Reichel trial. Additionally, a physician in Western Massachusetts was arrested and indicted for accepting kickbacks, violating HIPAA, and obstructing a criminal investigation. The physician is accused of accepting speaker fees and free meals, including a barbeque at her home, in exchange for prescribing two of Warner Chilcott's osteoporosis products. This case is still pending.

C. Obstacles Faced by the Government at Trial

Reichel's prosecution and acquittal is indicative of the obstacles implicit in prosecuting a senior executive for sales force misconduct. At trial, the government's case against Reichel rested on the proposition that Warner Chilcott's admittedly-aggressive sales culture amounted to a criminal conspiracy orchestrated by Reichel to violate the Anti-Kickback statute.2 The government's case largely consisted of testimony and documents from sales force personnel about the Med Ed and speaker programs and about the company's confrontational sales pitches. In the end, however, the court instructed the jury that Reichel could not be convicted of conspiring to violate the Anti-Kickback Statute merely because the company was aggressive and sought to cultivate business relationships or goodwill through its Med Ed and speaker programs. Rather, the court instructed that the burden fell to the government to prove that at least part of the purpose of the alleged remunerations (i.e., the speaker fees and Med Ed programs) was to effect a quid pro quo transaction. It further instructed that the government had the burden of proving that Reichel and at least one co-conspirator agreed to violate the law (in this case the Anti-Kickback Statute offense alleged in the indictment). Although the government put on a large amount of testimonial and documentary evidence as to the highly aggressive sales culture at Warner Chilcott, it struggled to convince the jury that this sales culture was more than just an aggressive strategy, but rather amounted to a criminal conspiracy, orchestrated by Reichel and others to violate the law.

During the course of the trial the government also sought to show a disparity between Warner Chilcott's official compliance guidelines and sales representatives' admittedly non-compliant behavior in the field as examples of a wink-and-nod compliance culture fostered by Reichel. Reichel's counsel aggressively argued, however, that the conduct of these sales representatives was not at his direction. Rather, he argued, this misconduct was the product of "rogue" sales representatives and district managers who testified at trial as immunized cooperating witnesses.

D. Conclusion

We will continue to monitor the evolving developments on the scope and application of the Anti-Kickback Statute and the impact of the Yates Memo. In the meantime, the Reichel trial demonstrates that, although the government may be able to extract a substantial corporate criminal plea based on sales force misconduct, it faces difficulty proving criminal charges against individual senior executives–particularly where executives have layers of managerial distance from sales personnel in the field.

Footnotes

1 Additionally, the company admitted that it had made unsubstantiated and unsupported superiority claims when marketing Actonel and Atelvia, claiming that these products were superior to other bisphosphonate osteoporosis drugs because of their "mechanism of action." Sales representatives were instructed to tell physicians that Actonel and Atelvia were superior because they penetrated more deeply into the bone and then exited more quickly, although there was no head-to-head study supporting this claim.
2 Although Reichel was not charged with prior authorization manipulation or misconduct related to HIPAA, the government alleged that sales representatives provided benefits to doctors' office staff in exchange for filling out and submitting the prior authorization forms.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.